Literature DB >> 21953138

Predictors of liver transplant eligibility for patients with hepatocellular carcinoma in a safety net hospital.

Amit G Singal1, Vincent Chan, Yonas Getachew, Richard Guerrero, Joan S Reisch, Jennifer A Cuthbert.   

Abstract

BACKGROUND: Liver transplantation for patients with hepatocellular carcinoma (HCC) affords excellent long-term survival but is limited to patients with early stage tumors. Predictors for orthotopic liver transplantation eligibility are not well defined for patients in a safety-net hospital system. AIMS: To clarify the clinical presentation of HCC and define predictors for early stage disease in a racially diverse safety-net hospital system.
METHODS: We retrospectively reviewed records of patients with HCC presenting to a large urban county hospital between January 1998 and October 2007. Logistic regression analysis was used to find predictors of OLT eligibility.
RESULTS: Of the 266 patients with HCC, 62% had multiple tumors, 47% had portal vein thrombosis and only 22% were potential liver transplant candidates based on Milan criteria. Male gender (OR 0.33; 95% CI 0.17-0.65) and AFP levels > 20 ng/mL (OR 0.22; 95% CI 0.11-0.45) were negative predictors of liver transplant eligibility. Age, race, and underlying viral liver disease were not significant predictors of early tumor stage.
CONCLUSIONS: A minority of HCC patients in a safety-net hospital are eligible for liver transplant at the time of diagnosis. Men have more advanced tumors at presentation, which may be related to more aggressive tumor biology or differential rates of HCC surveillance.

Entities:  

Mesh:

Year:  2011        PMID: 21953138     DOI: 10.1007/s10620-011-1904-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Kathy Han; George N Tzimas; Jeffrey S Barkun; Peter Metrakos; Jean L Tchervenkov; Nir Hilzenrat; Phil Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

2.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.

Authors:  A Singal; M L Volk; A Waljee; R Salgia; P Higgins; M A M Rogers; J A Marrero
Journal:  Aliment Pharmacol Ther       Date:  2009-04-08       Impact factor: 8.171

4.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Authors:  George N Ioannou; James D Perkins; Robert L Carithers
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

5.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

6.  Ethnic differences in hepatocellular carcinoma: implications for liver transplantation.

Authors:  Nyingi Kemmer; Guy Neff; Michelle Secic; Victoria Zacharias; Tiffany Kaiser; Joseph Buell
Journal:  Dig Dis Sci       Date:  2007-06-12       Impact factor: 3.199

7.  Disparities in liver transplantation before and after introduction of the MELD score.

Authors:  Cynthia A Moylan; Carla W Brady; Jeffrey L Johnson; Alastair D Smith; Janet E Tuttle-Newhall; Andrew J Muir
Journal:  JAMA       Date:  2008-11-26       Impact factor: 56.272

8.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

Authors:  Shian-Yang Peng; Wei J Chen; Po-Lin Lai; Yun-Ming Jeng; Jin-Chuan Sheu; Hey-Chi Hsu
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

9.  Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States.

Authors:  Avo Artinyan; Brian Mailey; Nicelio Sanchez-Luege; Joshua Khalili; Can-Lan Sun; Smita Bhatia; Lawrence D Wagman; Nicholas Nissen; Steven D Colquhoun; Joseph Kim
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

10.  Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States.

Authors:  Robert J Wong; Douglas A Corley
Journal:  Dig Dis Sci       Date:  2009-01-01       Impact factor: 3.199

View more
  12 in total

1.  Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis.

Authors:  Sherean Farvardin; Jaimin Patel; Maleka Khambaty; Olutola A Yerokun; Huram Mok; Jasmin A Tiro; Adam C Yopp; Neehar D Parikh; Jorge A Marrero; Amit G Singal
Journal:  Hepatology       Date:  2016-10-01       Impact factor: 17.425

2.  Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma.

Authors:  Benjamin Yip; James M Wantuck; Lily H Kim; Robert J Wong; Aijaz Ahmed; Gabriel Garcia; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

Review 3.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 4.  Liver transplantation for hepatocellular carcinoma.

Authors:  Jerome Byam; John Renz; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2013-02       Impact factor: 7.293

5.  Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Eimile Dalton-Fitzgerald; Jasmin Tiro; Pragathi Kandunoori; Ethan A Halm; Adam Yopp; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-11       Impact factor: 11.382

6.  Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up.

Authors:  Amit G Singal; Tushar D Dharia; Peter F Malet; Saleh Alqahtani; Song Zhang; Jennifer A Cuthbert
Journal:  BMJ Open       Date:  2013-09-03       Impact factor: 2.692

7.  Early predictors of outcomes of hospitalization for cirrhosis and assessment of the impact of race and ethnicity at safety-net hospitals.

Authors:  V V Pavan Kedar Mukthinuthalapati; Samuel Akinyeye; Zachary P Fricker; Moinuddin Syed; Eric S Orman; Lauren Nephew; Eduardo Vilar-Gomez; James Slaven; Naga Chalasani; Maya Balakrishnan; Michelle T Long; Bashar M Attar; Marwan Ghabril
Journal:  PLoS One       Date:  2019-03-06       Impact factor: 3.240

8.  Value of KPNA4 as a diagnostic and prognostic biomarker for hepatocellular carcinoma.

Authors:  Mingxing Xu; Hao Liang; Kun Li; Shu Zhu; Zhicheng Yao; Ruiyun Xu; Nan Lin
Journal:  Aging (Albany NY)       Date:  2021-02-01       Impact factor: 5.682

9.  United States women receive more curative treatment for hepatocellular carcinoma than men.

Authors:  Stephanie Cauble; Ali Abbas; Luis Balart; Lydia Bazzano; Sabeen Medvedev; Nathan Shores
Journal:  Dig Dis Sci       Date:  2013-06-29       Impact factor: 3.199

10.  Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma.

Authors:  Amit G Singal; Peng Zhang; Akbar K Waljee; Lakshmi Ananthakrishnan; Neehar D Parikh; Pratima Sharma; Pranab Barman; Venkataramu Krishnamurthy; Lu Wang; Stewart C Wang; Grace L Su
Journal:  Clin Transl Gastroenterol       Date:  2016-05-26       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.